{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:38:20Z","timestamp":1790735900538,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["18-323"],"award-info":[{"award-number":["18-323"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001537","name":"The University of Auckland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jchromb.2024.124211","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T23:46:33Z","timestamp":1718667993000},"page":"124211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Improved method for quantification of intact oxaliplatin by ultra high performance liquid chromatography-inductively coupled plasma mass spectrometry: Applications to clinical and speciation studies"],"prefix":"10.1016","volume":"1243","author":[{"given":"John","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hartinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-5503","authenticated-orcid":false,"given":"Mark","family":"McKeage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124211_b0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14656566.2012.643870","article-title":"Oxaliplatin: a review of approved uses","volume":"13","author":"Stein","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jchromb.2024.124211_b0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jchromb.2024.124211_b0015","unstructured":"Anonymous, ESMO Clinical Practice Guidelines: Gastrointestinal Cancers, 2017."},{"key":"10.1016\/j.jchromb.2024.124211_b0020","unstructured":"Anonymous, National Comprehensive Cancer Network Guidelines for Treatment of Cancer by Site."},{"key":"10.1016\/j.jchromb.2024.124211_b0025","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: A critical review","volume":"6","author":"Graham","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jchromb.2024.124211_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0731-7085(00)00377-0","article-title":"Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin","volume":"24","author":"Morrison","year":"2000","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124211_b0035","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1007\/s00216-005-3302-5","article-title":"Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry","volume":"382","author":"Brouwers","year":"2005","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2024.124211_b0040","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jms.1087","article-title":"Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate","volume":"41","author":"Brouwers","year":"2006","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2024.124211_b0045","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1002\/jps.21732","article-title":"New insights into the biotransformation and pharmacokinetics of oxaliplatin","volume":"98","author":"Jerremalm","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2024.124211_b0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpba.2017.01.045","article-title":"Quantification and clinical application of carboplatin in plasma ultrafiltrate","volume":"138","author":"Downing","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124211_b0055","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1039\/b716925f","article-title":"Platinum-specific detection and quantification of oxaliplatin and Pt(R, R-diaminocyclohexane)Cl-2 in the blood plasma of colorectal cancer patients","volume":"23","author":"Ip","year":"2008","journal-title":"J. Anal. At. Spectrom"},{"key":"10.1016\/j.jchromb.2024.124211_b0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jpba.2012.08.010","article-title":"A full validated hydrophilic interaction liquid chromatography\u2013tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates","volume":"71","author":"Ito","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124211_b0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jchromb.2008.10.055","article-title":"Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry","volume":"876","author":"Zhang","year":"2008","journal-title":"J. Chromatogr., B-Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2024.124211_b0070","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1039\/b907011g","article-title":"Quantification of cisplatin, carboplatin and oxaliplatin in spiked human plasma samples by ICP-SFMS and hydrophilic interaction liquid chromatography (HILIC) combined with ICP-MS detection","volume":"24","author":"Falta","year":"2009","journal-title":"J. Anal. At. Spectrom"},{"key":"10.1016\/j.jchromb.2024.124211_b0075","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1021\/js980287m","article-title":"Development of HPLC conditions for valid determination of hydrolysis products of cisplatin","volume":"88","author":"El-Khateeb","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2024.124211_b0080","unstructured":"Citron Trial Study Registration."},{"key":"10.1016\/j.jchromb.2024.124211_b0085","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/1471-2407-13-495","article-title":"Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients","volume":"13","author":"Han","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jchromb.2024.124211_b0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1385\/MO:19:4:261","article-title":"Pharmacokinetics of oxaliplatin in humans","volume":"19","author":"Ehrsson","year":"2002","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jchromb.2024.124211_b0095","first-page":"5970","article-title":"In-vitro cytotoxicity, protein-binding, red-blood-cell partitioning, and biotransformation of oxaliplatin","volume":"53","author":"Pendyala","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.jchromb.2024.124211_b0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00001813-199803000-00004","article-title":"Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters","volume":"9","author":"Gamelin","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jchromb.2024.124211_b0105","unstructured":"Anonymous, Bioanalytical Method Validation Guidance for Industry, in: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (Ed.), U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2018."},{"key":"10.1016\/j.jchromb.2024.124211_b0110","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2024.124211_b0115","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.4155\/bio-2017-0214","article-title":"Matrix effects and application of matrix effect factor","volume":"9","author":"Zhou","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2024.124211_b0120","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1038\/s41598-017-04383-4","article-title":"Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation","volume":"7","author":"Han","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224002204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224002204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T20:40:57Z","timestamp":1721508057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224002204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":24,"alternative-id":["S1570023224002204"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124211","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved method for quantification of intact oxaliplatin by ultra high performance liquid chromatography-inductively coupled plasma mass spectrometry: Applications to clinical and speciation studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124211"}}